Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00341172 · ClinicalTrials.gov registry record
The Effects of Genetic Differences Among AIDS Patients on Cytomegalovirus Retinitis
A clinical trial, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 2,232
- Enrollment target
NCT00341172: Completed study, sponsored by National Cancer Institute (NCI).
NCT00341172 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 2,232 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00341172 has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 2,232 participants
- Enrollment target
Study Summary
This study will evaluate the role of certain gene variants on the onset and course of cytomegalovirus (CMV) retinitis-a severe infection affecting the eye-in patients with AIDS. Symptoms include blurry vision, eye pain, photophobia, floaters, eye redness, and impaired vision. Left untreated, it can cause blindness. The study is done in collaboration with investigators of the Longitudinal Studies of the Ocular Complications of AIDS (LSOCA) at the Johns Hopkins University School of Medicine. The purpose of the LSOCA study is to learn about how HIV and other infections associated with AIDS and their treatments affect people's eyes and sight. Blood samples previously collected from patients participating in the LSOCA study will be analyzed for gene variants. These differences will then be correlated with the patients' clinical data to try to discover the role of gene differences among patients on the following: susceptibility to CMV and related problems; development and course of CMV; and response to HAART (highly active antiretroviral treatment), particularly in CMV onset and pathology. The study will use blood samples and clinical information previously collected from patients during their participation in LSOCA. The materials will be identified with a numerical code linking the samples and clinical data. No additional procedures will be performed on patients for this study.
Primary Outcome
this study is complete
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,232 participants |
| Start Date | 2004-10-26 |
| Est. Completion | 2021-03-04 |
What the finished NCT00341172 record still lists
NCT00341172 is an observational study that tracks outcomes without assigning an intervention. Its 2,232 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT00341172 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00341172 about?
NCT00341172 is a clinical study titled "The Effects of Genetic Differences Among AIDS Patients on Cytomegalovirus Retinitis". This study will evaluate the role of certain gene variants on the onset and course of cytomegalovirus (CMV) retinitis-a severe infection affecting the eye-in patients with AIDS. Symptoms include blurry vision, eye pain, photophobia, floaters, eye redness, and impaired vision. Left untreated, it can ...
What is the current status of trial NCT00341172?
This trial is currently completed. The enrollment target is 2,232 participants. The study started on 2004-10-26. Estimated completion is 2021-03-04.
Who is sponsoring clinical trial NCT00341172?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06831929 · 2,232 participants · NA
HPV Ends Here: Increasing Uptake of the HPV Vaccine
- NCT06939803 · 2,236 participants · NA
AI-driven Clinical Decision Support to Reduce Hospital-Acquired Venous Thromboembolism: Study Protocol for the VTE-AI Randomized Trial.
- NCT04889872 · 2,250 participants · NA
PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR
- NCT06805513 · 2,250 participants · Phase 3
Actual Use Trial of Tadalafil 5 mg
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI